Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2008
12/04/2008WO2008145963A1 2-oxo-2- (2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl) -acetamide derivatives and related compounds as antifungal agents
12/04/2008WO2008145843A1 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
12/04/2008WO2008145842A2 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
12/04/2008WO2008145841A1 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
12/04/2008WO2008145840A2 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas
12/04/2008WO2008145839A1 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
12/04/2008WO2008145838A2 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas
12/04/2008WO2008145789A1 Use of compounds derived from benzamidine methanesulphonate or a pharmaceutically acceptable salt thereof, for example imatinib mesylate, for the preparation of a drug for the treatment of neurodegenerative niemann-pick c disease (npc)
12/04/2008WO2008145759A1 New silver(i) compounds and their use in pharmaceutical compositions for the treatment, prophylaxis and prevention of infections
12/04/2008WO2008145697A1 Cancer treatment combination therapy comprising vinflunine and trastuzumab
12/04/2008WO2008145688A2 Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
12/04/2008WO2008145681A2 Ccr2 receptor antagonists and uses thereof
12/04/2008WO2008145678A1 Pyrazolopyrimidinone kinase inhibitor
12/04/2008WO2008145562A1 Non-nucleoside reverse transcriptase inhibitors
12/04/2008WO2008145524A2 4,4-disubstituted piperidine derivatives
12/04/2008WO2008145403A1 Processes related to making capecitabine
12/04/2008WO2008145398A1 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
12/04/2008WO2008145365A2 Treatment of surfactants with cyclodextrins
12/04/2008WO2008145335A1 Combination of a 5ht7 receptor ligand and an opioid receptor ligand
12/04/2008WO2008145281A2 Formulations containing triazinones and iron
12/04/2008WO2008145252A1 Pharmaceutical formulation comprising pramipexole
12/04/2008WO2008145243A1 Pyridazinone derivatives
12/04/2008WO2008145242A1 Aryl ether pyridazinone derivatives
12/04/2008WO2008145159A1 Blood withdrawal device comprising components for stabilizing the homocysteine level and/or for inhibiting the continuous formation of homocysteine in blood samples, serum samples or blood plasma samples
12/04/2008WO2008145143A1 Once daily oral dosage form comprising tacrolimus
12/04/2008WO2008145135A1 Antidepressiva for treatment of metabolic syndrome
12/04/2008WO2008145119A1 Transdermal tobacco alkaloid reservoir patch
12/04/2008WO2008145095A2 Amino acid-mineral-peptide complex, especially quantum-mechanically modified, as a medicament for the treatment of dementia diseases
12/04/2008WO2008144996A1 Stable pharmaceutical cucurbitacin liquid composition
12/04/2008WO2008144982A1 Compounds with 7-member cycle and the pharmaceutical use thereof for preventing and treating diabetes and metabolism syndrome
12/04/2008WO2008144956A1 New ambroxol compounds, their preparation processes and uses
12/04/2008WO2008144942A1 Sesquiterpene formulations, kits and methods of use thereof
12/04/2008WO2008144933A1 Cinnamoyl inhibitors of transglutaminase
12/04/2008WO2008144931A1 Compositions and methods for modulating gated ion channels
12/04/2008WO2008144925A1 Iap bir domain binding compounds
12/04/2008WO2008144919A1 Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
12/04/2008WO2008144916A1 Method of reducing side effects of isoniazid
12/04/2008WO2008144915A1 Improvement of mood, memory and cognitive function with pyridoxal 5'-phosphate
12/04/2008WO2008144914A1 Treatment of tardive dyskinesia with pyridoxal 5'-phosphate
12/04/2008WO2008144888A1 Formulations for the oral administration of therapeutic agents and related methods
12/04/2008WO2008144880A1 Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof
12/04/2008WO2008144836A1 Sulphated xylans for treatment or prophylaxis of respiratory diseases
12/04/2008WO2008144820A1 Treatment of chronic lung disease
12/04/2008WO2008127710A3 Methods for treating cancer resistant to erbb therapeutics
12/04/2008WO2008127640A3 Substituted benzimidazoles
12/04/2008WO2008127381A3 Artemisinin derivatives
12/04/2008WO2008126024A3 Oxazolidinone antibiotic derivatives
12/04/2008WO2008125901A3 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof
12/04/2008WO2008122638A3 Process for preparing pramipexole dihydrochloride tablets
12/04/2008WO2008119771A3 Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors
12/04/2008WO2008119741A3 3-imidazolyl-indoles for the treatment of proliferative diseases
12/04/2008WO2008115973A3 Aminopyrimidines useful as kinase inhibitors
12/04/2008WO2008115088A8 Use of rhodamine 6g in the form of a medicinal agent for treating malignant neoplasms and amiloidoses
12/04/2008WO2008114141A3 Composition comprising rutin and polyunsaturated fatty acid having an inhibitory activity on 5 alpha-reductase
12/04/2008WO2008113072A3 Gpcr enhanced neuroprotection to treat brain injury
12/04/2008WO2008111916A8 Glycosphingolipid-aided intracellular delivery of cargo molecules
12/04/2008WO2008109511B1 Nucleic acid compounds for inhibiting fcer2 gene expression and uses thereof
12/04/2008WO2008109352A3 Nucleic acid compounds for inhibiting akt gene expression and uses thereof
12/04/2008WO2008108834A3 Inhibitors of the mevalonate pathway of streptococcus pneumoniae
12/04/2008WO2008108647A3 Enhancement of anticancer therapy by flavonoids
12/04/2008WO2008108378A3 Bicyclic oxomorpholine derivative
12/04/2008WO2008104512A3 Novel polymorphs of aprepitant and processes for preparation
12/04/2008WO2008104408A3 Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
12/04/2008WO2008099144A3 Tgf-beta stimulant and further agent to reduce side effects
12/04/2008WO2008094992A3 2-aminopyridine derivatives useful as kinase inhibitors
12/04/2008WO2008094181A3 Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
12/04/2008WO2008093247A3 Medicament for the treatment of endometriosis
12/04/2008WO2008091701A9 Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
12/04/2008WO2008091465A3 Peg and targeting ligands on nanoparticle surface
12/04/2008WO2008085872A8 Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
12/04/2008WO2008082887A3 Inhibitors of poly(adp-ribose)polymerase
12/04/2008WO2008082608A3 Interleukin-15 antagonists for the treatment of anemia
12/04/2008WO2008079933A3 Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
12/04/2008WO2008079728A3 Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
12/04/2008WO2008079697A3 Method of treating mucin deficiency with an active pharmaceutical and related composition
12/04/2008WO2008073942A3 Pharmaceutical compositions and their methods of use
12/04/2008WO2008073858A9 Cancer chemoprevention strategy based on loss of imprinting of igf2
12/04/2008WO2008073154A3 Methods and compositions for treating disease
12/04/2008WO2008070350A3 Methods and compositions related to wrapping of dehydrons
12/04/2008WO2008067863A3 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting mpt
12/04/2008WO2008067464A3 NEW Aβ CONFORMER SELECTIVE ANTI-Aβ GLOBULOMER MONOCLONAL ANTIBODIES
12/04/2008WO2008067389A3 Modulation of sod protein synthesis for the treatment of neurodegenerative diseases
12/04/2008WO2008066783A3 Therapeutic materials and methods
12/04/2008WO2008062905A3 Heteromonocyclic compound and use thereof
12/04/2008WO2008057579A3 Dosage forms and co-administration of an opioid agonist and an opioid antagonist
12/04/2008WO2008055348A8 Reduced-hangover alcoholic beverage comprising turmeric
12/04/2008WO2008054792A3 Na+/k+-atpase-specific peptide inhibitors/activators of src and src family kinases
12/04/2008WO2008054475A3 Neuraminidase inhibitors and uses thereof
12/04/2008WO2008048589A3 Compounds and methods for treatment of hcv
12/04/2008WO2008039641A3 Substituted phenylether-thienopyridone compounds with antibacterial activity
12/04/2008WO2008035315A3 Inhibitors of phosphodiesterase type-iv
12/04/2008WO2008033749A3 Quinazoline based egfr inhibitors containing a zinc binding moiety
12/04/2008WO2008033747A3 Multi-functional small molecules as anti-proliferative agents
12/04/2008WO2008033739A3 Benzimidazole carboxamide derivatives
12/04/2008WO2008031004A3 Binding of proanthocyanidins with bacteria and bacterial components
12/04/2008WO2008030617A3 Cancer therapy with cantharidin and cantharidin analogs
12/04/2008WO2008030389A3 Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
12/04/2008WO2008028193A3 Colon-targeted oral formulations of cytidine analogs
12/04/2008WO2008024277A3 Kw-3902 conjugates that do not cross the blood-brain barrier
12/04/2008WO2008024139B1 Inhibitors of fatty acid amide hydrolase
1 ... 2964 2965 2966 2967 2968 2969 2970 2971 2972 2973 2974 2975 2976 2977 2978 2979 2980 2981 2982 2983 2984 ... 7860